PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential

PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential

PD-1/PD-L1 immune checkpoint inhibitors show potential for cervical cancer treatment. However, low response rates suggest that patient selection based on PD-L1 protein expression is not optimal. Here, we evaluated different PD-L1 detection methods and studied transcriptional regulation of PD-L1/PD-L...

Full description

Bibliographic Details
Main Authors:	Jossie Rotman, Leontine A. S. den Otter, Maaike C. G. Bleeker, Sanne S. Samuels, A. Marijne Heeren, Margaretha G. M. Roemer, Gemma G. Kenter, Henry J. M. A. A. Zijlmans, Nienke E. van Trommel, Tanja D. de Gruijl, Ekaterina S. Jordanova
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-12-01
Series:	Frontiers in Immunology
Subjects:	cervical cancer programmed cell death ligand 1 programmed cell death ligand 2 fluorescence in situ hybridization RNAish immunohistochemistry
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2020.596825/full

Similar Items

‘DURVIT’: a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment
by: J. Rotman, et al.
Published: (2018-09-01)

GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression
by: Young Wha Koh, et al.
Published: (2017-03-01)

Peripheral blood T lymphocytes are downregulated by the PD-1/PD-L1 axis in advanced gastric cancer
by: Witold Zgodzinski, et al.
Published: (2018-04-01)

Percentages of PD-1+CD4+T cells and PD-L1+DCs are increased and sPD-1 level is elevated in patients with immune thrombocytopenia
by: Yingying Wang, et al.
Published: (2018-04-01)

Downregulation of Immunosuppressive Molecules, PD-1 and PD-L1 but not PD-L2, in the Patients with Multiple Sclerosis
by: Mohammad Reza Javan, et al.
Published: (2016-08-01)

The Expression Levels and Concentrations of PD-1 and PD-L1 Proteins in Septic Patients: A Systematic Review
by: Mutiara Indah Sari, et al.
Published: (2022-08-01)

High Expression of PD-L1 Is Associated with Better Survival in Pancreatic/Periampullary Cancers and Correlates with Epithelial to Mesenchymal Transition
by: Nishant Thakur, et al.
Published: (2021-03-01)

Nivolumab Enhances In Vitro Effector Functions of PD-1+ T-Lymphocytes and Leishmania-Infected Human Myeloid Cells in a Host Cell-Dependent Manner
by: Christodoulos Filippis, et al.
Published: (2017-12-01)

Expression of PD-1 and PD-L1 in Breast Carcinoma: Research Protocol for a Cohort Study
by: Shreya Ghosh, et al.
Published: (2023-11-01)

Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer
by: Di ZHANG, et al.
Published: (2019-06-01)

Targeting PD-1/PD-L1 inhibits rejection in a heterotopic tracheal allograft model of lung transplantation
by: Taisuke Kaiho, et al.
Published: (2023-11-01)

Efficacy and Safety of PD-1/PD-L1 Inhibitor as Single-Agent Immunotherapy in Endometrial Cancer: A Systematic Review and Meta-Analysis
by: Mohd Nazzary Mamat @ Yusof, et al.
Published: (2023-08-01)

PD-L1 Over-Expression Varies in Different Subtypes of Lung Cancer: Will This Affect Future Therapies?
by: Asad Ullah, et al.
Published: (2022-08-01)

The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer
by: Hui Yang, et al.
Published: (2020-03-01)

PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer
by: Jong-Mu Sun
Published: (2017-03-01)

Analysis of the Correlation between Molecular Structural Differences of PD-1/PD-L1 Inhibitors and Adverse Events
by: Tongji XIE, et al.
Published: (2020-07-01)

Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
by: Chao Cheng, et al.
Published: (2022-09-01)

Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma
by: Nan Zhang, et al.
Published: (2024-02-01)

Comparison of Immune Checkpoint Molecules <i>PD-1</i> and <i>PD-L1</i> in Paired Primary and Recurrent Glioma: Increasing Trend When Recurrence
by: Wei Yu, et al.
Published: (2022-02-01)

Soluble programmed death-1 (sPD-1) and programmed death ligand 1 (sPD-L1) as potential biomarkers for the diagnosis and prognosis of glioma patients
by: Liu Shujun, et al.
Published: (2020-01-01)

Expression of PD-L1 in Urothelial Carcinoma and its Association with Clinicopathological Parameters
by: Gurupriya Anand, et al.
Published: (2022-01-01)

PD-1/PD-L1 Correlates With the Efficacy of the Treatment of Concurrent Chemoradiotherapy in Cervical Cancer
by: Hanqun Zhang, et al.
Published: (2022-05-01)

Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave
by: Xinfang Yu, et al.
Published: (2021-11-01)

Expression of Programmed Cell Death-1 (PD-1) and Its Ligand (PD-L1) in Breast Cancers and Its Association with Clinicopathological Parameters
by: Anoushika Mehan, et al.
Published: (2022-03-01)

PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma
by: Mengjia Song, et al.
Published: (2024-12-01)

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
by: Joon Seon Song, et al.
Published: (2019-10-01)

Advances of the Role of Lung Cancer Driver Gene and PD-1/PD-L1 Pathway Interaction in the Tumorigenesis and Progression of Non-small Cell Lung Cancer
by: Yan SHI, et al.
Published: (2017-11-01)

Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations
by: Jiqiao Yang, et al.
Published: (2019-07-01)

Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China
by: Lin Zhang, et al.
Published: (2022-01-01)

Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy
by: Rilan Bai, et al.
Published: (2022-05-01)

Expression and Clinical Significance of PD-1 and PD-L1 in Pulmonary Carcinoids
by: Mingbiao LI, et al.
Published: (2016-12-01)

PD‐1/PD‐L1 negative schwannoma mimicking obstructive bronchial malignancy: A case report
by: Daibing Zhou, et al.
Published: (2020-08-01)

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
by: Maureen L. Drakes, et al.
Published: (2018-05-01)

Anti-programmed death ligand 1 (PD-L1) inhibitors in metastatic gastric cancer
by: Jang Ho Cho, et al.
Published: (2017-12-01)

Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer
by: Andrzej Kowalski, et al.
Published: (2021-07-01)

Advances of PD-1/PD-L1 Signaling Pathway in Immune Escape and Treatment for  Non-small Cell Lung Cancer
by: Cheng LIN, et al.
Published: (2014-10-01)

Clinical and Prognostic Significance of PD-L1, Beclin 1 and Fascin 1 Immunohistochemical Expression in Colorectal Carcinoma
by: Sabah Mohamed Hanafy, et al.
Published: (2023-10-01)

Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations
by: Xiang Chen, et al.
Published: (2024-02-01)

Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma
by: Meiyan Zhu, et al.
Published: (2024-04-01)

Progress of research on PD-1/PD-L1 in leukemia
by: Huizhen Cao, et al.
Published: (2023-09-01)